28 results on '"Dufay, E."'
Search Results
2. L’aide d’un système à la décision pharmaceutique dans le surdosage des anticancéreux oraux
- Author
-
Potier, A., primary, Ade, M., additional, Dony, A., additional, Weber, A., additional, Duffourc, M.-O., additional, Boschetti, E., additional, Divoux, E., additional, Demoré, B., additional, and Dufay, E., additional
- Published
- 2022
- Full Text
- View/download PDF
3. Apport d’un système d’aide à la décision pharmaceutique dans la supplémentation martiale des anémies bilantées
- Author
-
Potier, A., primary, Ade, M., additional, Huguet, A., additional, Dony, A., additional, Duffourc, M.-O., additional, Boschetti, E., additional, Divoux, E., additional, Demoré, B., additional, and Dufay, E., additional
- Published
- 2022
- Full Text
- View/download PDF
4. La conciliation des traitements médicamenteux : logigramme d’une démarche efficiente pour prévenir ou intercepter les erreurs médicamenteuses à l’admission du patient hospitalisé
- Author
-
Doerper, S., Morice, S., Piney, D., Dony, A., Baum, T., Perrin, F., Guillaume, V., Vidal, A., Ferry, O., Peter, N., Azizi, Y., Vouaux, V., Rosa, D., and Dufay, E.
- Published
- 2013
- Full Text
- View/download PDF
5. Apport d’un système d’aide à la décision pharmaceutique dans la détection d’interactions médicamenteuses méconnues
- Author
-
Ade, M., Potier, A., Huguet, A., Dony, A., Pilven, P., Demore, B., and Dufay, E.
- Published
- 2024
- Full Text
- View/download PDF
6. 5PSQ-034 Homogeneity of opinion expert on CLEO scale when applied to 50 modelled pharmaceutical interventions
- Author
-
Viaud, C, primary, Potier, A, additional, Bouet, J, additional, Ade, M, additional, Dony, A, additional, Divoux, E, additional, Willemin, AS, additional, Sergent, M, additional, Titah, C, additional, De Abreu, N, additional, Hamdad, W, additional, Demore, B, additional, and Dufay, E, additional
- Published
- 2022
- Full Text
- View/download PDF
7. 5PSQ-126 AVICENNE as a clinical decision support in thromboprophylaxis: just because the patient’s situation is improving doesn’t mean there’s no drug related problem!
- Author
-
Potier, A, primary, Houssemand, T, additional, Barreiros, P, additional, Rodet, M, additional, Divoux, E, additional, Boschetti, E, additional, Duffourc, MO, additional, Dony, A, additional, Demore, B, additional, and Dufay, E, additional
- Published
- 2021
- Full Text
- View/download PDF
8. 5PSQ-208 Pharmaceutical algorithms targeting anticoagulant therapy: impact of AVICENNE clinical decision support in patient safety
- Author
-
Potier, A, primary, Dufay, E, additional, Dony, A, additional, Divoux, E, additional, Isernia, C, additional, Arnoux, LA, additional, Piney, D, additional, Jay, N, additional, and Demore, B, additional
- Published
- 2021
- Full Text
- View/download PDF
9. Iatrogénie médicamenteuse nosocomiale et gestion des risques d’erreur médicamenteuse: à propos de l’analyse des notifications du réseau REEM
- Author
-
Bernheim, C., Schmitt, E., and Dufay, E.
- Published
- 2005
- Full Text
- View/download PDF
10. Collaboration entre le département d’information médicale et la pharmacie : évaluation de son impact financier
- Author
-
Giroux, A., primary, Dony, A., additional, Mervelay, V., additional, Berquand, I., additional, and Dufay, E., additional
- Published
- 2017
- Full Text
- View/download PDF
11. Sécuriser l’administration des médicaments injectables : rédaction d’un thésaurus de protocoles d’administration médicamenteux des anti-infectieux injectables pour un service d’HAD
- Author
-
Gauthier, M., primary, Dony, A., additional, Piney, D., additional, Barbosa, G., additional, Divoux, E., additional, and Dufay, E., additional
- Published
- 2017
- Full Text
- View/download PDF
12. Abstracts of papers Rational use of drugs: 18th European Symposium on Clinical Pharmacy
- Author
-
Dukes, M. N. G., Elenbaas, Robert M., Tognoni, G., Smith, Dorothy L., Lunde, Inga, Leufkens, H. G. M., Hekster, Y. A., Bakker, A., Ostino, G., Petri, H., Sturmans, F., Banta, H. D., Rutten, F. F. H., Martens, L. L., Noyce, P. R., Merkus, F. W. H. M., de Jong-v.d.Berg, Lolkje, Haaijer-Ruskamp, Flora, Dukes, Graham, Vidgren, B. -M., Vidgren, S., Martini, N., Sala, M. L., Scroccaro, G., Olivencia, P., McLcod, D. C., Coln, W. G., Hartzcma, A. G., Thaver, C. F., Rodriguez-Sasiain, J. M., Sangroniz, B., Mauleon, M. D., Wood, M. A., Martinez, M. J., Leinebø, O., Saugen, J. N., Marini, P., Olivato, R., Alberola, C., Cruz-Martos, E., Cruz, T., Marfagon, N., de Tejada, A. Herreros, Denig, P., Haaijer-Ruskamp, F. M., Wesseling, H., Versluis, A., Gascón, M. P., Horne, Robert, Hough, Jane, Klazinga, N. S., van Everdingen, J. J. -E., van den Broek, P. J., Roberts, D. K., Veitch, G. B. A., Tan K. K. C., Holland D. A., Allwood M. C., Nicholls, A., Astobieta, A., Calvo, R., Rodriquez-Sasiain, J. M., Barriquand, D., Pochon, C., Aulagner, G., Vial, A., Dumarest, C., Maire, P. H., Jelliffe, R. W., Brouwers, J. R. B. J., Cramer, K., Gulyas, J., vd Kam, H. J., Sijtsma, J., Donadio, C., Tramonti, G., Garcea, G., Costagli, M., Lucchetti, A., Giordani, R., Paizis, G., Pierotti, R., Falcone, G., Bianchi, C., Gallastegui C., Farré R., Jiménez I., Mangues M. A., Guasch E., Ginovart G., Sagrera X., Raspall F., Queralto J. M., Kovarik, J. M., Rademaker, C. M. A., Verhoef, J., Silvestri, L., Caputo, M., Andrew, M., Toverud, E. -L., Jimenez I., Castro I., Alvarez E., Altimiras J., van de Leur, J. J. J. P. M., Muller, N. F., Van Turnhout, J. M., Mendizabal, L., Sasiain, J. M. Rodriguez, Morana, G., Ofstad, K. Moss, Timenes, A. -M., Vroom, J. K. F., de Jong-van den Berg, L. T. W., van den Berg, P. B., de Gier, J. J., Ferres J., Recoder O., Sanchez Rio T., Garcia M. P., Julia A., Balet A., Farre R., Manques M. A., Berod, T., Dufay, E., Naveau, C., Combe, M., Sauvageon, A., Hansen, Erik Wind, Christensen, Jens Dencker, Lie-A-Huen, L., Kinqma, J. H., Meijer, D. K. P., Le Meur, F., Isoard, P., Salek, M. S., Finlay, A. Y., Khan, G. K., Luscombe, D. K., Stuurman, A., Boidin, M. P., Wallenius, K., Ojala, R., Kariluoto, A., Ikonen, M., Paes, A. H. P., Blom, A. Th. G., Bakker, A., Wallenius, S., Enlund, H., Vainio, K., Codina, C., Roca, M., Sardà, P., Corominas, N., Massó, J., Ribas, J., Kentra, K., Myllyntausta, M., Saarenpää, M., Airaksinen, M. S. A., Mendarte, L., Rimola, A., Meisters, R., Hekster, Y., Janssen, W., Cox, A., Kempen, R., Aerdts, S. J. A., van Dalen, R., Clasener, H. A. L., Festen, J., Schjphorst, PP, Benraad, HB, van Asten, P., de Wit, R., Muller, N. F., Limbeek, R. J. G., Nagel, H. G. M., Mgyboom, R. H. B., Stricker, B. H. C., van den Berg, B. A. M., Nelen, T. H. A., Tijssen, T. A. G., Wassink, P., Wassink-L'Ortije, M. J. E., Gascón, P., Selva, C., Bassons, T., Pardo, C., Mas, M. P., Saqalés, M., Sánchez, F., Mercade, V., Pujol, R., Agustí, C., Cano, M., Gurrera, T., Gorchs, M., Fabregas, X., Murgui, L. L., Verdaguer, A., Witjes, W. P. J., Vollaard, E. J., Crul, B. J. P., Limpens, C., Ahonen, K., Klaukka, T., Vohlonen, I., Martikainen, J., Goldenberg, Daniel, Brodsky, Andres, Aparici, Ines, Argeri, Cecilia, Goldenberg D., Saidman C., Sevinski L., Allevato N., Mujico B., Ubogui J., Dorfman P., Rodriguez Lupo L., Varela M., Higa J., Fourrier, Annie, Larrouturou, Philippe, Samarran, Claire, Huchet, Jacqueline, Barber, N. D., Party, N., Wilson, P., Eide, Grethe, Horvei, Kari, Kruse-Jensen, Angelika, Wold, Ingrid, Møark, Turid, Barrett, C. W., Tugwell, A. C., Søndergaard, B., Rasmussen, M., Davidsen, F., Hey, H., Kierkeby, L., Riis, L., Korhonen, M., Vidgren, P., Ojanen, T., Vidqren, M., Ferrés J., Sanchez T., Gallastequi C., Julià A., Herings, R. M. C., Stricker, B. H. Ch., Janssen, A. J. H. H., Dinter, Heike, Janssen, A. J. H. M., Barbaut, X., Proust, S., Amlagner, G., Eskens, F. A. L. M., Clasener, H. A. L., Vollaard, E. J., Arnoldussen, E., Sieradzki, E., Wanat-Słupska, E., Zlółkowska, M., Pankowska, I., Mazur, R., Ksiazkiewicz, B., Jankowski, A., Marzec, A., Marzec, C., Marzec, M. O., Marzec, J. P., Marzec, A., Mungall, D. R., Portnoy, Lynne, Lucas, F., Kadir, F., Pijpers, A., Vulto, A., Zuidema, J., Tan, K. K. C., Sutton, P., Samu, Antal, Murphy, John E., Chapman, Ronnie, Wieringa, Nicolien, de Gier, J. J., Rolloos, J., Voesten, M. T. P. J., de Meijer, P. J. J., de Koning, G. H. P., Salek, S., Reerink, E., Mungall, D. R., Farrow, L., Raskob G., Rosenbloom D., Hull R., Ferres J., Torras A., Farre R., Recorder O., Garcia M. P., Torras C., Cubellsl J., Font, M., Madridejos, R., Catalán, A., Huguet, M., Franquesa, N., Gratacós, J., Martinez, M., Saltó, A., van der Kleijn, E., ter Wee, R. J. M., Holmberg, N., and Brenninkmeijer, R. F.
- Published
- 1989
- Full Text
- View/download PDF
13. Utiliser le dossier pharmaceutique pour concilier la capacité informationnelle du DP
- Author
-
Dony, A., primary, Baum, T., additional, Potier, A., additional, Doerper, S., additional, Guillaume, V., additional, Azizi, Y., additional, Vidal, A., additional, Piney, D., additional, and Dufay, E., additional
- Published
- 2015
- Full Text
- View/download PDF
14. Aide à la prescription des héparines de bas poids moléculaire en milieu médical
- Author
-
Pierson, H, primary, Thilly, N, additional, Collard, C, additional, Lepaux, DJ, additional, Lecompte, T, additional, and Dufay, E, additional
- Published
- 1997
- Full Text
- View/download PDF
15. Fighting medication errors: Results of a study and reflections on causes and ways for prevention.
- Author
-
Lepaux, D.J., Schmitt, E., and Dufay, E.
- Subjects
MEDICATION errors ,DRUG utilization ,QUALITY assurance - Abstract
The authors carried out a pilot study at the Jury lès Metz hospital in Metz, France. The aim was to test methods of detecting and calculating the rate of medication errors (MER) focussing on four types of MER as they were directly accessible to detection and quantification: prescribing error rate (PER), delivering error rate (DER), i.e. discrepancies between prescribed and dispensed quantities, rate of medicines missing at the time of administration rate (MMR), and the repartition error rate (RER), the rate of errors made by nurses in the repartition of medicines into trays or containers.In total 3398 prescriptions containing 15699 lines of prescription were analysed. The various mean error rates per prescription (95% confidence interval) were: Prescribing Error Rate=1.92% [1.74–2.10], Delivering Error Rate (DER)=2.7% [2.2–3.2], Missing Medication Rate=6.9% [6.1–7.7] and Picking and Repartition Error Rate=5.9% [4.4–7.4].On the basis of these results and an analysis of the literature and of a case of a fatal error which was publicized in France the authors reflect on the causes and measures for the prevention of medical errors. They conclude that in order to prevent drug induced morbidity, a systematic reduction of medication errors is needed and this requires setting up a multi-professional management quality assurance system of the drug utilization process. Furthermore, if medication errors occur they should not be covered up but analysed and remedied if possible. [ABSTRACT FROM AUTHOR]
- Published
- 2002
16. Enhancing pharmaceutical decision support system: evaluating antithrombotic-focused algorithms for addressing drug-related problems.
- Author
-
Potier A, Ade M, Demoré B, Divoux E, Dony A, and Dufay E
- Abstract
Objectives: To evaluate the efficacy of integrating antithrombotic-focused pharmaceutical algorithms (PAs) into a pharmaceutical decision support system (PDSS) for detecting drug-related problems (DRPs) and facilitating pharmaceutical interventions., Methods: A set of 26 PAs (12.4%) out of a total of 210 were created to model patient situations involving antithrombotics, and their contributions were compared with the entire PDSS system.The observational prospective study was conducted between November 2019 and June 2023 in two health facilities with 1700 beds. Pharmacists, who followed a DRP resolution strategy to support human supervision, analysed alerts generated by these encoded PAs. They registered their interventions and the acceptance by physicians., Results: From 3290 alerts analysed targeting antithrombotics, the pharmacists issued 1170 interventions of which 676 (57.8%) were accepted by physicians. With the 184 other PAs, from 9484 alerts the pharmacists issued 3341 interventions of which 1785 were accepted (53.4%).Results indicate that the detection of DRPs related to antithrombotics usage represents a high proportion of those detected by the PDSS, highlighting the importance of incorporating tailored PA elements at the modelling stage., Conclusions: The system evolves alongside the physiological changes associated to the patient situations, adapts the alerts and complements the current care. Therefore, we recommend that all PDSS should integrate specific algorithms targeting DRPs associated with antithrombotics to enhance pharmaceutical interventions and improve patient safety., Competing Interests: Competing interests: None declared., (© European Association of Hospital Pharmacists 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
17. Dynamized ultra-low dilution of Ruta graveolens disrupts plasma membrane organization and decreases migration of melanoma cancer cell.
- Author
-
Fuselier C, Dufay E, Berquand A, Terryn C, Bonnomet A, Molinari M, Martiny L, and Schneider C
- Subjects
- Humans, Cell Membrane, Plant Extracts pharmacology, Melanoma, Cutaneous Malignant, Ruta, Melanoma, Skin Neoplasms
- Abstract
Cutaneous melanoma is a cancer with a very poor prognosis mainly because of metastatic dissemination and therefore a deregulation of cell migration. Current therapies can benefit from complementary medicines as supportive care in oncology. In our study, we show that a dynamized ultra-low dilution of Ruta Graveolens leads to an in vitro inhibition of migration on fibronectin of B16F10 melanoma cells, as well as a decrease in metastatic dissemination in vivo . These effects appear to be due to a disruption of plasma membrane organization, with a change in cell and membrane stiffness, associated with a disorganization of the actin cytoskeleton and a modification of the lipid composition of the plasma membrane. Together, these results demonstrate, in in vitro and in vivo models of cutaneous melanoma, an anti-cancer and anti-metastatic activity of ultra-low dynamized dilution of Ruta graveolens and reinforce its interest as complementary medicine in oncology.
- Published
- 2023
- Full Text
- View/download PDF
18. [First French-speaking days of users of decision support system in clinical pharmacy: Feedback and perspectives].
- Author
-
Robert L, Rousselière C, Beuscart JB, Gautier S, Delporte L, Lafci G, Gerard E, Négrier L, Mary A, Johns E, Payen A, Ducommun R, Ferret L, Voirol P, Skalafouris C, Ade M, Potier A, Dufay E, Beney J, Frery P, Drouot S, Feutry F, Corny J, Odou P, and Décaudin B
- Abstract
Clinical decision support systems (CDSS) are tools that have been used for several years by clinical pharmacy teams to support pharmaceutical analysis, with a perspective of contributing to the quality of care in collaboration with the other health care team members. These tools require both technical, logistical and human resources. The growing use of these systems in different establishments in France and in Europe gave birth to the idea of meeting to share our experiences. The days organized in Lille in September 2021 aimed at proposing a time of exchange and reflection on the use of these CDSS in clinical pharmacy. A first session was devoted to feedback from each establishment. These tools are essentially used to optimize pharmaceutical analysis and to secure patient medication management. This session outlined the clear advantages and common limitations of these CDSS. Two research projects were also presented to put the use of these tools into perspective. The second session of these days, in the form of workshops, addressed 4 themes that surround the implementation of CDSS: their usability, the legal aspect, the creation of rules and their possible valorization. Common problems were raised, the resolution of which requires close collaboration. This is a first step proposing a beginning of harmonization and sharing that should be deepened in order not to lose the dynamics created between the different centers. This event ended with the proposal to set up two working groups around these systems: the creation and structuring of rules for the detection of risk situations and the common valorization of the work., (Copyright © 2023 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
19. Pharmaceutical algorithms set in a real time clinical decision support targeting high-alert medications applied to pharmaceutical analysis.
- Author
-
Potier A, Dufay E, Dony A, Divoux E, Arnoux LA, Boschetti E, Piney D, Dupont C, Berquand I, Calvo JC, Jay N, and Demoré B
- Subjects
- Algorithms, Humans, Pharmaceutical Preparations, Pharmacists, Prospective Studies, Decision Support Systems, Clinical, Drug-Related Side Effects and Adverse Reactions prevention & control
- Abstract
Background: Pharmaceutical analysis of the prescription has to prop up the quality of patients' medication management in a context of medication's risk acculturation. But this activity remains highly variable. Medication-related clinical decision support may succeed in reducing adverse drug events and healthcare costs., Purpose: This study aims to present AVICENNE as a real time medication-related clinical decision support (rt-CDS) applied to pharmaceutical analysis and its ability to detect Drug related problems (DRP) consecutively resolved by pharmacists. Basic procedures A Medication-related rt-CDS is created by integrating the software PharmaClass® (Keenturtle), 5 health data streams on the patient and Pharmaceutical algorithms (PA). PA are created by modeling the pharmaceutical experiment about DRP and the thread of their criticality. They are partially encoded as computerized rules in Pharmaclass® allowing alerts' issue. An observational prospective study is conducted during 9-months among 1000 beds in 2 health facilities. The first step is to identify alerts as DRP; their resolution follows with clear guidelines worked out for the pharmaceutical analysis. A basis on predictive positive values (PPV) of the PA is being built today helping to know the performance of DRP detection and resolution. Main findings 71 PA are encoded as rules into Pharmaclass®: 40 targeted serious adverse drug events. 1508 alerts are analyzed by pharmacists. Among them 921 DRPs were characterized and 540 pharmaceutical interventions transmitted of which 219 were accepted by prescribers. Three PPV are defined depending on software, pharmacist and patient. Principal conclusion Clinical pharmacy societies should host, share and update a national corpus of PA and exploit its educational interest., (Copyright © 2022 Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
20. Anti-Tumoral and Anti-Angiogenic Effects of Low-Diluted Phenacetinum on Melanoma.
- Author
-
Fuselier C, Quemener S, Dufay E, Bour C, Boulagnon-Rombi C, Bouland N, Djermoune EH, Devy J, Martiny L, and Schneider C
- Abstract
Melanoma is the most aggressive form of skin cancer and the most rapidly expanding cancer in terms of worldwide incidence. If primary cutaneous melanoma is mostly treated with a curative wide local excision, malignant melanoma has a poor prognosis and needs other therapeutic approaches. Angiogenesis is a normal physiological process essential in growth and development, but it also plays a crucial role in crossing from benign to advanced state in cancer. In melanoma progression, angiogenesis is widely involved during the vertical growth phase. Currently, no anti-angiogenic agents are efficient on their own, and combination of treatments will probably be the key to success. In the past, phenacetin was used as an analgesic to relieve pain, causing side effects at large dose and tumor-inducing in humans and animals. By contrast, Phenacetinum low-dilution is often used in skin febrile exanthema, patches profusely scattered on limbs, headache, or flushed face without side effects. Herein are described the in vitro , in vivo , and ex vivo anti-angiogenic and anti-tumoral potentials of Phenacetinum low-dilution in a B16F1 tumor model and endothelial cells. We demonstrate that low-diluted Phenacetinum inhibits in vivo tumor growth and tumor vascularization and thus increases the survival time of B16F1 melanoma induced-C57BL/6 mice. Moreover, Phenacetinum modulates the lung metastasis in a B16F10 induced model. Ex vivo and in vitro , we evidence that low-diluted Phenacetinum inhibits the migration and the recruitment of endothelial cells and leads to an imbalance in the pro-tumoral macrophages and to a structural malformation of the vascular network. All together these results demonstrate highly hopeful anti-tumoral, anti-metastatic, and anti-angiogenic effects of Phenacetinum low-dilution on melanoma. Continued studies are needed to preclinically validate Phenacetinum low-dilution as a complementary or therapeutic strategy for melanoma treatment., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Fuselier, Quemener, Dufay, Bour, Boulagnon-Rombi, Bouland, Djermoune, Devy, Martiny and Schneider.)
- Published
- 2021
- Full Text
- View/download PDF
21. Clinical and economic impact of medication reconciliation in cancer patients: a systematic review.
- Author
-
Herledan C, Baudouin A, Larbre V, Gahbiche A, Dufay E, Alquier I, Ranchon F, and Rioufol C
- Subjects
- Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Drug-Related Side Effects and Adverse Reactions prevention & control, Humans, Medication Reconciliation economics, Randomized Controlled Trials as Topic, Medication Reconciliation methods, Neoplasms drug therapy, Neoplasms economics
- Abstract
Purpose: Medication reconciliation can reduce drug-related iatrogenesis by facilitating exhaustive information transmission at care transition points. Given the vulnerability of cancer patients to adverse drug events, medication reconciliation could provide a significant clinical benefit in cancer care. This review aims to synthesize existing evidence on medication reconciliation in cancer patients., Methods: A comprehensive search was performed in the PubMed/Medline, Scopus, and Web of Science databases, associating the keywords "medication reconciliation" and "cancer" or "oncology.", Results: Fourteen studies met the selection criteria. Various medication reconciliation practices were reported: performed at admission or discharge, for hospitalized or ambulatory patients treated with oral or parenteral anticancer drugs. In one randomized controlled trial, medication reconciliation decreased clinically significant medication errors by 26%. Although most studies were non-comparative, they highlighted that medication reconciliation led to identification of discrepancies and other drug-related problems in up to 88% and 94.7% of patients, respectively. The impact on post-discharge healthcare utilization remains under-evaluated and mostly inconclusive, despite a trend toward reduction. No comparative economic evaluations were available but one study estimated the benefit:cost ratio of medication reconciliation to be 2.31:1, suggesting its benefits largely outweigh its costs. Several studies also underlined the extended pharmacist time required for the intervention, highlighting the need for further cost analysis., Conclusion: Medication reconciliation can reduce adverse drug events in cancer patients. More robust and economic evaluations are still required to support its development in everyday practice.
- Published
- 2020
- Full Text
- View/download PDF
22. The clinical impact of medication reconciliation on admission to a French hospital: a prospective observational study.
- Author
-
Dufay E, Morice S, Dony A, Baum T, Doerper S, Rauss A, and Piney D
- Abstract
Objective: This study was designed to assess the clinical impact of medication reconciliation using two criteria: the number of inpatients who had experienced at least one medication error; the severity of the potential harm associated with these detected errors., Method: The study was a prospective observational one. The eligible population included patients aged 65 and over subjected to medication reconciliation at admission. The potential severity of medication errors was evaluated independently by the physician in charge of the patient and by the pharmacist involved in the medication reconciliation process. Severity assessment took account of the drug(s) involved in the error, the type of medication error, and the patient's clinical and biological data., Results: From January 2011 to September 2012, 1799 medication errors were recorded among the 1670 patients subjected to medication reconciliation who were hospitalised from the emergency department. At least one medication error occurred for 744 (44.6%) of these patients. There were 87 medication errors associated with potentially major severity (5.6%). These concerned 67 patients (4.2%). The most prevalent error was omission. Cardiovascular and anticoagulant drugs were the drugs most frequently involved in these serious medication errors. Arrhythmia, haemorrhage, thrombosis, hyperglycaemia and hypoglycaemia were identified as the most likely harms that could have occurred., Conclusions: The detection of cases of serious potential harm shows the clinical impact of medication reconciliation. It would be interesting to perform a multicentred assessment using indicators such as the number of inpatients experiencing at least one serious medication error. This could help to promote medication reconciliation as essential for patient safety., Competing Interests: Competing interests: None declared.
- Published
- 2016
- Full Text
- View/download PDF
23. [A Woman Experienced Severe Thrombocytopenia When Treated With Fluvastatin].
- Author
-
Potier A, Dony A, Crapsky A, Ferry O, Piney D, and Dufay E
- Subjects
- Acetaminophen administration & dosage, Acetaminophen therapeutic use, Binding, Competitive, Comorbidity, Cytochrome P-450 CYP2C9 metabolism, Cytochrome P-450 CYP2C9 Inhibitors pharmacokinetics, Drug Substitution, Drug Synergism, Fatty Acids, Monounsaturated administration & dosage, Fatty Acids, Monounsaturated pharmacokinetics, Fatty Acids, Monounsaturated therapeutic use, Female, Fluvastatin, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors administration & dosage, Hydroxymethylglutaryl-CoA Reductase Inhibitors pharmacokinetics, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Inactivation, Metabolic drug effects, Indoles administration & dosage, Indoles pharmacokinetics, Indoles therapeutic use, Middle Aged, Pravastatin therapeutic use, Recurrence, Valproic Acid administration & dosage, Valproic Acid adverse effects, Valproic Acid pharmacokinetics, Valproic Acid therapeutic use, Fatty Acids, Monounsaturated adverse effects, Hydroxymethylglutaryl-CoA Reductase Inhibitors adverse effects, Indoles adverse effects, Thrombocytopenia chemically induced
- Abstract
A 62-year-old woman treated with fluvastatin experienced three separate thrombocytopenic illnesses, severe on two occasions associated with nadir platelet count of 57 000/µL and 75 000/µL. The hospital pharmacist replaced fluvastatin by pravastatin during three stays. Platelet count has increased some days after this substitution. These results suggest that fluvastatin could be involved in these thrombocytopenic episodes., (© 2015 Société Française de Pharmacologie et de Thérapeutique.)
- Published
- 2015
- Full Text
- View/download PDF
24. Development and multi-centre evaluation of a method for assessing the severity of potential harm of medication reconciliation errors at hospital admission in elderly.
- Author
-
Doerper S, Godet J, Alexandra JF, Allenet B, Andres E, Bedouch P, Desbuquois AC, Develay-Rambourg A, Bauge-Faraldi O, Gendarme S, Gourieux B, Grain A, Long K, Loulière B, Roudot M, Roussel-Galle MC, Roux-Masson C, Thilly N, Dufay E, and Michel B
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Internal Medicine, Male, Patient Safety, Reproducibility of Results, Surveys and Questionnaires, Hospitalization statistics & numerical data, Medication Reconciliation methods, Pharmacy Service, Hospital standards, Research Design standards
- Abstract
Background: Medication reconciliation is a powerful process to correct medication errors (ME) resulting from miscommunicated information at transitions of care. This study aims to develop and evaluate a scoring method for assessing the severity of potential harm of ME intercepted by medication reconciliation at hospital admission in elderly., Methods: The development of the scoring method was based on a literature search and the creation of a list of high-risk drugs used in outpatient care. The evaluation of the method was carried out in 7 French hospitals and was based on two criteria: the inter-rater reliability and acceptability. The assessment of the inter-rater reliability was based on intra-class correlation coefficient (ICC) calculations. Each hospital prospectively enrolled the 10 first patients aged 65 or older presenting with at least one ME. Seven blocks of 10 patients were formed. After randomization, each block was rated by practitioners from 3 hospitals. The assessment of the acceptability was based on a satisfaction questionnaire., Results: A clinical algorithm was developed. The inter-rater reliability of the method was validated by the overall agreement of the 7 hospitals ratings. The agreement was at least substantial (ICC>0.60) and in most of cases almost perfect (ICC>0.80). The acceptability of the method was judged as satisfactory., Conclusion: This multi-centre project has validated an instrument for assessing the severity of potential harm of ME intercepted by medication reconciliation. This will allow studies to be conducted with large cohorts of patients in order to develop epidemiological databases of ME of potential clinical significance., (Copyright © 2015 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
25. Improving ACE inhibitor use in patients hospitalized with systolic heart failure: a cluster randomized controlled trial of clinical practice guideline development and use.
- Author
-
Thilly N, Briançon S, Juillière Y, Dufay E, and Zannad F
- Subjects
- Angiotensin-Converting Enzyme Inhibitors administration & dosage, Cardiology Service, Hospital standards, Female, Humans, Male, Middle Aged, Physician's Role, Practice Patterns, Physicians' standards, Quality of Health Care standards, Randomized Controlled Trials as Topic, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Heart Failure drug therapy, Practice Guidelines as Topic
- Abstract
Rationale, Aims and Objectives: The efficacy of angiotensin-converting enzyme (ACE) inhibitors in treating heart failure is well established, but there is concern that these agents are underutilized. This study aimed to evaluate the effect of developing and implementing Clinical Practice Guidelines (CPGs) on the quality of care given to patients receiving ACE inhibitors for systolic heart failure., Methods: Twenty cardiology units in Lorraine (France) were randomized to an experimental (n = 10) or a control group (n = 10). In each experimental unit, doctors were involved in drafting and implementing CPGs; those at control units were not. Practice surveys were conducted in all units before and after the intervention; 723 patients with heart failure and less than 75 years old were included. The main outcome was compliance with the CPGs., Results: Before intervention, clinicians in both groups were already compliant with CPGs relating to indications and contra-indications, adverse effects management, concomitant therapy and monitoring of biologic factors. After intervention, adherence to others CPGs was generally better in the experimental group. Compliance with the CPG relating to ACE inhibitor dose on discharge was higher in the experimental group (P = 0.003). Compliance with CPGs relating to increasing ACE inhibitors doses (P < 0.0001) and the contents of the discharge letter (P = 0.02) improved in all units between the two periods., Conclusions: These results suggest that doctors involved in drafting and implementing CPGs are more likely to comply with them.
- Published
- 2003
- Full Text
- View/download PDF
26. [Angiotensin-converting enzyme inhibitors in congestive heart failure: clinical practice guidelines].
- Author
-
Thilly N, Zannad F, Dufay E, Juillière Y, and Briançon S
- Subjects
- Humans, Angiotensin-Converting Enzyme Inhibitors administration & dosage, Angiotensin-Converting Enzyme Inhibitors adverse effects, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Heart Failure drug therapy
- Abstract
Angiotensin-converting enzyme (ACE) inhibitors are, at present, the cornerstone of therapy for congestive heart failure. Nevertheless, international literature and regional data have reported their underutilisation in the practice of cardiology. Despite the abundance of consensus conferences, none deal specifically with a therapeutic strategy using ACE inhibitors. In this context, clinical practice guidelines on the management of systolic heart failure with ACE inhibitors have been drafted in Lorraine by hospital cardiologists. The guidelines were formulated using a standardised procedure, combining a literature analysis and the opinions of experts. Seventeen guidelines were finally adopted, under four headings: indications and contraindications for ACE inhibitors; dosages and approaches to treatment monitoring; the management of adverse effects; and contraindications for concomitant therapy. The drafting of the clinical practice guidelines is the first step in a quality improvement programme, initiated in 1999 in the cardiology wards of the region.
- Published
- 2003
- Full Text
- View/download PDF
27. [Prophylaxis of venous thromboembolism in medical patients: from medical decision tools to the use of low molecular weight heparin].
- Author
-
Thilly N, Pierson H, Collard C, Lecompte T, and Dufay E
- Subjects
- Aged, Decision Making, France, Hospitals, General, Humans, Middle Aged, Risk Factors, Anticoagulants therapeutic use, Decision Support Techniques, Heparin, Low-Molecular-Weight therapeutic use, Thromboembolism prevention & control, Venous Thrombosis prevention & control
- Abstract
In France, low molecular weight heparins are largely used for prophylaxis of venous thromboembolic disease in medical patients. Although clinical trials show their efficacy in some particular clinical situations, there is no consensus about their use in non-surgical patients. A consequence is a wide disparity of prophylaxis of venous thromboembolic disease regimens: such a situation was observed during a practice survey in two medical units of the general hospital of Lunéville. So, prior assessment for pharmacists and physicians was carried out to determine tools which guide decision-making. These comprise clinical practice guidelines, a record card which allows the scoring of risk for venous thromboembolic disease and a clinical algorithm leading to the appropriate prescription according to the risk and the haematological results. A second concomitant practice survey was organized in the same two units in order to measure the appropriateness of the decision-making tools in medical practice. The four-month study included 108 medical patients. The process was successful because: (1) validated practices are improved, particularly in respect of biological monitoring during treatment, and (2) the disparity of therapeutic strategies is highly reduced, the clinical practice guidelines being followed in 81 per cent of all cases. Despite the lack of consensus, heightened awareness of the attendant risk in many medical conditions allows appropriate prophylactic measures to be taken. These measures need decision-making tools that are easy to use and that improve heparin prescribing and thus healthcare quality.
- Published
- 1998
28. [Delayed acute pancreatitis after treatment with L-asparaginase. A case report].
- Author
-
Pecquenard L, Damay M, Naveau C, Lemarchand V, Dufay E, and Berod T
- Subjects
- Acute Disease, Child, Humans, Male, Asparaginase adverse effects, Pancreatitis chemically induced
- Published
- 1990
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.